LAEKNA-B (02105): Xie Ling and Zhou Jian appointed as members of the Nomination and Corporate Governance Committee.
Kailai Pharmaceuticals-B (02105) announced that as of December 12, 2025, Ms. Xie Ling, an Executive Director, and Mr. Zhou Jian, an Independent Non-executive Director, have been appointed as members of the company's Nomination and Corporate Governance Committee.
LAEKNA-B (02105) announced that as of December 12, 2025, Ms. Xie Ling, an executive director, and Mr. Zhou Jian, an independent non-executive director, have been appointed as members of the company's Nomination and Corporate Governance Committee.
Related Articles
Shanghai Fosun Pharmaceutical (02196): Ketoprofen patches approved for clinical trials.
BEKE-W (02423) spent $3 million on December 11th to repurchase 513,000 shares.
Yunnan Energy New Material (002812.SZ) plans to increase the issuance to acquire 100% stake in Zhongke Hualian, improving the layout of advanced production capacity.
Shanghai Fosun Pharmaceutical (02196): Ketoprofen patches approved for clinical trials.
BEKE-W (02423) spent $3 million on December 11th to repurchase 513,000 shares.
Yunnan Energy New Material (002812.SZ) plans to increase the issuance to acquire 100% stake in Zhongke Hualian, improving the layout of advanced production capacity.
